<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00125346</url>
  </required_header>
  <id_info>
    <org_study_id>CTBM100C2301</org_study_id>
    <nct_id>NCT00125346</nct_id>
  </id_info>
  <brief_title>Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Subjects</brief_title>
  <acronym>EVOLVE</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Trial to Assess the Efficacy and Safety of Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis (CF) Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      Lung infections are a chronic problem for patients with cystic fibrosis (CF). Some patients
      with CF may have a type of bacteria called Pseudomonas aeruginosa in their lungs that can
      cause infections or make their symptoms worse. Tobramycin inhalation solution (TOBI) is an
      approved antibiotic, which is inhaled directly into the lungs, and can be used to manage
      these infections. Tobramycin inhalation powder (TIP) is a new, experimental powder
      formulation of tobramycin that is inhaled directly into the lungs using a T-326 inhaler. The
      purpose of this research study is to determine if TIP is safe and effective when compared to
      placebo (a powder with no medicine) treatment.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    per Data Monitoring Committee recommendation
  </why_stopped>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Forced expiratory volume in 1 second (FEV1) measured at week 1 and week 5.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time until first antipseudomonal antibiotic (an antibiotic used to treat bacteria of a certain type [the genus pseudomonas]) is used</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative changes in FEV1 % predicted for patients who received TIP starting at visit 1 and for patients who received placebo starting at week 9, compared to all subsequent visits.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative change in FEV1 % predicted for patients who received placebo from week 5 to week 13</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative change in FEV1 % predicted for patients who received placebo (from the average of four assessments [weeks 1, 2, 5, and 9] to week 13)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in susceptibility of pseudomonas to the antibiotic during the study measured at weeks 5, 9, 13, 17, 21, and 25, and change from baseline in quantity of pseudomonas found in sputum during the study measured at weeks 5, 9, 13, 17, 21,</measure>
  </secondary_outcome>
  <enrollment type="Actual">98</enrollment>
  <condition>Cystic Fibrosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tobramycin Inhalation Powder</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of cystic fibrosis patients with Pseudomonas aeruginosa infection.

          -  Male and female subjects between 6 and 21 years of age at the time of screening.

          -  FEV1 at screening must be between 25% and 80% of normal predicted values.

        Exclusion Criteria:

          -  Known local or systemic hypersensitivity to aminoglycosides or inhaled antibiotics.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>For information on a site near you, call 1-800-244-7668 Option &quot;2&quot;</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information on a site near you, call 1-800-244-7668 Option &quot;2&quot;</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information on a site near you, call 1-800-244-7668 Option &quot;2&quot;</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information on a site near you, call 1-800-244-7668 Option &quot;2&quot;</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information on a site near you, call 1-800-244-7668 Option &quot;2&quot;</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information on a site near you, call 1-800-244-7668 Option &quot;2&quot;</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information on a site near you, call 1-800-244-7668 Option &quot;2&quot;</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information on a site near you, call 1-800-244-7668 Option &quot;2&quot;</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information on a site near you, call 1-800-244-7668 Option &quot;2&quot;</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information on a site near you, call 1-800-244-7668 Option &quot;2&quot;</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information on a site near you, call 1-800-244-7668 Option &quot;2&quot;</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information on a site near you, call 1-800-244-7668 Option &quot;2&quot;</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information on a site near you, call 1-800-244-7668 Option &quot;2&quot;</name>
      <address>
        <city>Oak Lawn</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information on a site near you, call 1-800-244-7668 Option &quot;2&quot;</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information on a site near you, call 1-800-244-7668 Option &quot;2&quot;</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information on a site near you, call 1-800-244-7668 Option &quot;2&quot;</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information on a site near you, call 1-800-244-7668 Option &quot;2&quot;</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information on a site near you, call 1-800-244-7668 Option &quot;2&quot;</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information on a site near you, call 1-800-244-7668 Option &quot;2&quot;</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information on a site near you, call 1-800-244-7668 Option &quot;2&quot;</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information on a site near you, call 1-800-244-7668 Option &quot;2&quot;</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information on a site near you, call 1-800-244-7668 Option &quot;2&quot;</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information on a site near you, call 1-800-244-7668 Option &quot;2&quot;</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information on a site near you, call 1-800-244-7668 Option &quot;2&quot;</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information on a site near you, call 1-800-244-7668 Option &quot;2&quot;</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information on a site near you, call 1-800-244-7668 Option &quot;2&quot;</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information on a site near you, call 1-800-244-7668 Option &quot;2&quot;</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information on a site near you, call 1-800-244-7668 Option &quot;2&quot;</name>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information on a site near you, call 1-800-244-7668 Option &quot;2&quot;</name>
      <address>
        <city>Curitiba</city>
        <state>PR</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information on a site near you, call 1-800-244-7668 Option &quot;2&quot;</name>
      <address>
        <city>Campinas</city>
        <state>San Paolo</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information on a site near you, call 1-800-244-7668 Option &quot;2&quot;</name>
      <address>
        <city>Florianopolis</city>
        <state>SC</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information on a site near you, call 1-800-244-7668 Option &quot;2&quot;</name>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information on a site near you, call 1-800-244-7668 Option &quot;2&quot;</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information on a site near you, call 1-800-244-7668 Option &quot;2&quot;</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information on a site near you, call 1-800-244-7668 Option &quot;2&quot;</name>
      <address>
        <city>Sainte-Foy</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information on a site near you, call 1-800-244-7668 Option &quot;2&quot;</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information on a site near you, call 1-800-244-7668 Option &quot;2&quot;</name>
      <address>
        <city>Vi√±a del Mar</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information on a site near you, call 1-800-244-7668 Option &quot;2&quot;</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information on a site near you, call 1-800-244-7668 Option &quot;2&quot;</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information on a site near you, call 1-800-244-7668 Option &quot;2&quot;</name>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information on a site near you, call 1-800-244-7668 Option &quot;2&quot;</name>
      <address>
        <city>Tijuana</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Former Serbia and Montenegro</country>
  </removed_countries>
  <link>
    <url>http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=2540</url>
    <description>Click here for more information about the study.</description>
  </link>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2005</study_first_submitted>
  <study_first_submitted_qc>July 28, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2005</study_first_posted>
  <last_update_submitted>October 10, 2011</last_update_submitted>
  <last_update_submitted_qc>October 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2011</last_update_posted>
  <responsible_party>
    <name_title>external affairs</name_title>
    <organization>novartis</organization>
  </responsible_party>
  <keyword>Tobramycin Inhalation Powder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Respiratory Aspiration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobramycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

